Please assess the completion status of the following clinical trial:

Trial Title: Long Term Safety of Naldemedine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~1. Subjects aged 18 to 80 years inclusive at the time of informed consent~2. Subjects must have non-malignant chronic pain treated and must have opioid induced constipation (OIC)~3. Subjects must be treated with a stable opioid regimen at a total daily dose on average of ≥ 30 mg equivalents of oral morphine sulfate~4. Subjects may or may not be on a routine laxative regimen at the time of Screening~Exclusion Criteria~1. Evidence of significant structural abnormalities of the gastrointestinal (GI) tract~2. Evidence of active medical diseases affecting bowel transit~3. History of pelvic disorders that may be a cause of constipation~4. Surgery (except for minor procedures) within 60 days of Screening~5. History of chronic constipation prior to starting analgesic medication or any potential non-opioid cause of bowel dysfunction that may be a major contributor to the constipation (e.g. mechanical GI obstruction)~6. Subjects who have never taken laxatives for the treatment of OIC~7. Current use of any prohibited medication including opioid antagonists, partial or mixed agonists/antagonists

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Naldemedine (Type: EXPERIMENTAL): Participants received 0.2 mg naldemedine tablets orally once daily for 52 weeks.
- Placebo (Type: PLACEBO_COMPARATOR): Participants received matching placebo tablets orally once daily for 52 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).